This analysis evaluates the correlation between biomarkers for immunotherapy eligibility, indicating a strong relationship between MMR loss and MSI status.
Key Points
A strong correlation was observed between MMR protein loss identified via IHC and MSI status determined by NGS.
Among 139 tumor samples analyzed, 12 were classified as MSI-High, with 10 showing MMR protein loss.
IHC is widely used due to its accessibility and cost-effectiveness while NGS provides higher accuracy and detailed genomic insights.
Combining IHC and NGS can enhance diagnostic precision and optimally guide immunotherapy selection.